FTC Probes Teva Pharmaceuticals Over Alleged Patent Listing Violations for Inhalers

The Federal Trade Commission has initiated an inquiry into Teva Pharmaceuticals in response to the company’s refusal to delete certain inhaler patents from a pivotal federal database. This development comes after the Washington Post referenced confidential documents from the agency, highlighting concerns over potential patent listing violations. For more details, visit the source article.